HuMax-CD20 in Chronic Lymphocytic Leukemia

Inclusion Criteria:

Chronic Lymphocytic Leukemia
Circulating lymphocytes above a specific level
Circulating lymphocytes showing certain markers

Exclusion Criteria:

Previous treatment with rituximab or alemtuzumab within 6 months prior to enrollment in study.
Previous stem cell transplantation.
Received any of the following treatments within 4 weeks prior to entering this trial: A) Anti-cancer therapy, B) Glucocorticoids unless less than 10 mg per day, C) Radiotherapy.
HIV positivity.
Hepatitis B or hepatitis C.
Other cancerous diseases, except certain skin cancers and cervix cancer.
Certain serious medical conditions, including kidney or liver disease, some psychiatric illnesses, and stomach, heart, hormonal, nerve or blood diseases.
Participation in another trial with a different new drug 4 weeks prior to enrollment in study.
Current participation in any other clinical study.
Pregnant or breast-feeding women.
Women of childbearing age who are unable or unwilling to use adequate contraception.